Thus, ERK5 silencing or pharmacological inhibition compromises viability of numerous cancer cell lines, as well as impairs tumor growth in xenograft models (Reviewed in Gomez et al. (2016), Pereira and Rodrigues (2020), Stecca and Rovida (2019)). This evidence concerns the gene MAPK7 and neoplasm.